Favipiravir

Favipiravir

Favipiravir

Min.Order / FOB Price:Get Latest Price

1 Gram

Negotiable

  • Min.Order :1 Gram
  • Purity: 99
  • Payment Terms : L/C,D/P,T/T

Keywords

Favipiravir; 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE; 6-fluoro-3-hydroxypyrazine-2-carboxaMide; 2-Pyrazinecarboxamide,6-fluoro-3-hydroxy; UNII-EW5GL2X7E0; 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide; Favipiravir(API)

Quick Details

  • Appearance:white power
  • Application:coronavirus related
  • PackAge:DRUMS/CARTON
  • ProductionCapacity:10|Metric Ton|Week
  • Storage:in sealed air resistant place
  • Transportation:as customers demands

Superiority:

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Details:

Favipiravir, whose chemical name is 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antibody targeting RNAChemicalbook-dependent RNA polymerase (RdRp) developed by Japan’s Toyama Chemical Pharmaceutical Company Viral drugs, approved for marketing in Japan in March 2014, are used to treat new and recurrent influenza.

Favipiravir (favipiravir), chemically named 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antibody targeting RNA-dependent RNA polymerase (RdRp) developed by Japan’s Toyama Chemical Pharmaceutical Company Viral drugs, approved for marketing in the Japanese Chemicalbook in March 2014, are used to treat new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug released in March 2020 showed that the drug may have the effect of speeding up virus clearance and alleviating the progress of new coronavirus pneumonia.

Favipiravir exhibits anti-influenza virus activity. The IC50 ranges for influenza A virus, influenza B virus and influenza C virus are 0.013-0.48μg/ml, 0.039-0.089μg/ml, and 0.030-0.057μg/ml, respectively. In mammalian cell lines (MDCK cells, ChemicalbookVero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir at a concentration of up to 1,000 μg/ml showed no toxicity. Favipiravir induced lethal mutations in MDCK cells inoculated with seasonal influenza A (H1N1) virus.

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View